What is Stratedigm?
Stratedigm, Inc. is a prominent developer and manufacturer of advanced flow cytometry systems. Their product portfolio includes a range of benchtop flow cytometers, such as the S1000EON series, engineered for exceptional sensitivity and resolution. These systems are designed to meet the diverse needs of research institutions and laboratories, offering customizable configurations and automation capabilities. Stratedigm complements its hardware with intuitive software solutions and a commitment to technological longevity through its Anti-Obsolescence Guarantee. Manufactured in Silicon Valley, the company prioritizes product reliability and dedicated customer service.
How much funding has Stratedigm raised?
Stratedigm has raised a total of $92K across 1 funding round:
Debt
$92K
Debt (2021): $92K with participation from PPP
What's next for Stratedigm?
With the recent influx of expansion capital, Stratedigm is poised for significant scaling and market penetration. The substantial funding at this Series B/C stage suggests a strategic focus on enhancing production capabilities, expanding sales and marketing efforts, and potentially accelerating research and development for next-generation cytometry technologies. This investment will likely enable Stratedigm to solidify its competitive advantage and further its mission to provide high-quality, future-proof solutions to the global scientific community.
See full Stratedigm company page
